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| INTRODUCTION
Ideally, treatment of haemophilia should be prophylactic to minimize the emergence of bleeding events. This has spurred the development of modified coagulation factors with prolonged duration of action, conveniently reducing the required frequency of administration.
1 One example is nonacog beta pegol (N9-GP), a recombinant factor IX (FIX) with a 40-kDa polyethylene glycol (PEG40) moiety attached to an Nlinked glycan in the activation peptide, 2 which exhibits doubled recovery and a five-fold extension of the mean terminal half-life in humans arriving at a t ½ value of 93 hours. 3, 4 Unfortunately, modification of a coagulation factor is often accompanied by altered properties, potentially in a way that poses a challenge for the assay used to measure the biological activity against an unmodified counterpart. 5, 6 N9-GP activity can be accurately measured by a one-stage (OS)
FIX clotting assay when using select commercially available activated partial thromboplastin time (APTT) reagents, albeit a majority of APTT reagents under-or overestimate N9-GP activity when analyzed against a plasma-derived FIX standard. 7, 8 This awareness is of utmost importance in the clinical setting because erroneous estimates of N9-GP activity could result in suboptimal treatment of haemophilia B patients. Most, but not all, silica-based APTT reagents overestimate the N9-GP activity owing to silica-mediated precocious conversion to activated FIX (FIXa), a process catalyzed by activated factor XI (FXIa) and plasma kallikrein occurring during the contact activation phase preceding recalcification. 9 Here, we aimed at elucidating the mechanism underlying the underestimation of N9-GP activity observed with a heterogeneous group of APTT reagents. This intra-assay phenomenon is puzzling because the responsible reagents contain either ellagic acid, silica, or kaolin as the contact activator. Our findings allow us to propose a unifying mode by which a diverse set of APTT reagents exert similar effects.
| MATERIALS AND METHODS

| Materials and standard methods
N9-GP and non-PEGylated recombinant FIX (N9) were produced by Novo Nordisk A/S (Måløv, Denmark) as described. 
| Sampling under conditions mimicking the clotting phase and measurement of generated FIXa
N9-GP and N9 were reconstituted, prepared, and used as described.
9
Measurements of FIXa activity were performed using the Rox FIX-A kit as described 9 on samples taken 60 seconds after Ca 
Essentials
• Nonacog beta pegol (N9-GP) activity can be underestimated in clot method using diverse reagents.
• Mimicking clotting phase with representative reagents reveals impaired FIX and N9-GP activation.
• Polyethylene glycol conjugation amplifies contact activator-induced decrease in FIX activation.
• The reagent is a pivotal factor for accurate measurement of N9-GP activity in clinical samples. 
| FXIa amidolytic activity assay
| RESULTS AND DISCUSSION
The present study focused on APTT reagents previously shown to underestimate N9-GP activity in a OS FIX clotting assay and employed Actin FS, SynthASil and STA-C.K. Prest. 7, 11 They were selected to represent the broad spectrum of reagent compositions. Of particular interest is the fact that they are based on various contact activator surfaces, ie, ellagic acid, colloidal silica, and kaolin, respectively. Initially, we established that the presence of any of these APTT reagents significantly reduced the activation rates for both N9-GP and N9 (non-PEGylated). Most important in this context, the activation of N9-GP progressed slower than that of N9, a difference which was not seen in the absence of APTT reagent ( Figure 1 ). 2 These observations were valid regardless of whether the contact activation phase was allowed to precede recalcification or was omitted by supplementing the APTT reagent with added FXIa. Thus, it appeared to be justified and sufficient to mimic the clotting phase, and
we applied an experimental design where FXIa was added together with the APTT reagent (or the replacement for the complete reagent) immediately before recalcification. In this setup (Figure 1 ), the ratios between the rates of N9-GP and N9 activation in the presence of Actin FS or SynthASil were in good agreement with the degrees of underestimation of N9-GP activity seen in a recent two-center study, 7 and the results with STA-C.K. Prest were in line with those of an earlier study. 11 The presence of free PEG40 had no influence on the activation of either N9-GP or N9 using any of the underestimating reagents. Using a reagent (SynthAFax) whose presence gives the expected N9-GP activity recovery, 7 we noticed indistinguishable, marginally inhibited activations of N9-GP and N9.
A pronounced impairment of N9-GP activation in the presence of an underestimating APTT reagent was shown by gel electrophoretic visualization of formed FIXa in incubations of N9-GP and N9 with FXIa in the presence of SynthASil (Figure 2 ). An inevitable consequence of these findings is that N9-GP activity, when measured against a FIX standard in an assay influenced by the activation kinetics, such as a clotting assay, would be underestimated due to relatively slower conversion to FIXa. Moreover, these data support that the reason for N9-GP underestimation resides in the clotting phase and is independent of PEG-mediated adsorption to the contact activator. (and present report). In support of unique mechanisms being responsible for the oppositely erroneous estimations of N9-GP activity, free PEG40 cannot alleviate underestimation (ie, FXIa adsorption) but prevents overestimation (ie, N9-GP adsorption).
9
In conclusion, in order to avoid assay artefacts and obtain the anticipated recovery of N9-GP activity in the OS FIX clotting assay when using a FIX standard, one must select an APTT reagent which does not elicit any intra-assay adsorption event.
7 Albeit limited overdosage of N9-GP due to underestimation of its activity may not in itself pose a safety risk for the haemophilia B patients, the importance of accurate measurement is self-evident.
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